Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Frank McCormick is active.

Publication


Featured researches published by Frank McCormick.


Science | 1996

An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

James R. Bischoff; David Kirn; Angelica Williams; Carla Heise; Sharon Horn; Mike Muna; Lelia Ng; Julie Nye; Adam Sampson-Johannes; Ali Fattaey; Frank McCormick

The human adenovirus E1B gene encodes a 55-kilodalton protein that inactivates the cellular tumor suppressor protein p53. Here it is shown that a mutant adenovirus that does not express this viral protein can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53. Ectopic expression of the 55-kilodalton EIB protein in the latter cells rendered them sensitive to infection with the mutant virus. Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors. These data raise the possibility that mutant adenoviruses can be used to treat certain human tumors.


Cell | 1996

Wiskott–Aldrich Syndrome Protein, a Novel Effector for the GTPase CDC42Hs, Is Implicated in Actin Polymerization

Marc Symons; Jonathan M.J. Derry; Brian Karlak; Sharon Jiang; Vanessa Lemahieu; Frank McCormick; Uta Francke; Arie Abo

The Rho family of GTPases control diverse biological processes, including cell morphology and mitogenesis. We have identified WASP, the protein that is defective in Wiskott-Aldrich syndrome (WAS), as a novel effector for CDC42Hs, but not for the other Rho family members, Rac and Rho. This interaction is dependent on the presence of the G protein-binding domain. Cellular expression of epitope-tagged WASP produces clusters of WASP that are highly enriched in polymerized actin. This clustering is not observed with a C-terminally deleted WASP and is inhibited by coexpression with dominant negative CDC42Hs-N17, but not with dominant negative forms of Rac or Rho. Thus, WASP provides a novel link between CDC42Hs and the actin cytoskeleton, which suggests a molecular mechanism for many of the cellular abnormalities in WAS. The WASP sequence contains two novel domains that are homologous to other proteins involved in action organization.


Current Opinion in Genetics & Development | 1997

Signal transduction from multiple Ras effectors.

Michael E Katz; Frank McCormick

Ras proteins activate a signaling cascade through direct binding of the serine/threonine kinase Raf. They also activate additional signaling pathways that are essential for full biological activity. Candidate effectors for these pathways include RalGDS and phosphatidyl inositol 3 kinase, as well as several other Ras binding proteins the biochemical and biological properties of which are poorly understood.


Molecular and Cellular Biology | 1997

Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation.

Rong-Guo Qiu; Arie Abo; Frank McCormick; Marc Symons

The Rho family members Cdc42, Rac, and Rho play a central role in the organization of the actin cytoskeleton and regulate transcription. Whereas Rac and Rho have been implicated in transformation by oncogenic Ras, the role of Cdc42 in this process remains unknown. In this study, we found that Rat1 fibroblasts expressing constitutively active V12-Cdc42 were anchorage independent and proliferated in nude mice but failed to show enhanced growth in low serum. Similar to V12-Rac1-expressing Rat1 fibroblasts, V12-Cdc42 lines displayed a high frequency of multinucleated cells. Interestingly, coexpression of dominant negative N17-Rac1 blocked the V12-Cdc42-induced multinucleated phenotype but not growth in soft agar, indicating that Cdc42 controls anchorage independence in a Rac-independent fashion. We also showed that dominant negative N17-Cdc42 inhibited Ras focus formation and anchorage-independent growth and caused reversion of the transformed morphology, indicating that Cdc42 is necessary for Ras transformation. N17-Cdc42 caused only partial inhibition of Ras-induced low-serum growth, however. In contrast, whereas N17-Rac1 also effectively inhibited Ras-induced anchorage independence, it did not revert the morphology of Ras-transformed cells. N17-Rac1 strongly inhibited low-serum growth of Ras-transformed cells, however. Together, these data provide a novel function for Cdc42 in cell proliferation and indicate that Cdc42 and Rac play distinct roles in growth control and Ras transformation.


Current Opinion in Genetics & Development | 1994

Activators and effectors of ras p21 proteins.

Frank McCormick

Over the past year, major advances have been made in understanding the key steps involved in signaling pathways--from receptor tyrosine kinases to ras p21, and on to a cascade of serine/threonine kinases. A chain of specific protein-protein interactions is responsible for signal transduction. Components of the pathway are highly conserved between flies, nematodes and mammals, and constitute a primary signaling device in most cell types.


Molecular and Cellular Biology | 1993

Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro.

S. G. Macdonald; Craig M. Crews; Lelia Wu; J. Driller; R. Clark; R. L. Erikson; Frank McCormick

Raf-1 is a serine/threonine kinase which is essential in cell growth and differentiation. Tyrosine kinase oncogenes and receptors and p21ras can activate Raf-1, and recent studies have suggested that Raf-1 functions upstream of MEK (MAP/ERK kinase), which phosphorylates and activates ERK. To determine whether or not Raf-1 directly activates MEK, we developed an in vitro assay with purified recombinant proteins. Epitope-tagged versions of Raf-1 and MEK and kinase-inactive mutants of each protein were expressed in Sf9 cells, and ERK1 was purified as a glutathione S-transferase fusion protein from bacteria. Raf-1 purified from Sf9 cells which had been coinfected with v-src or v-ras was able to phosphorylate kinase-active and kinase-inactive MEK. A kinase-inactive version of Raf-1 purified from cells that had been coinfected with v-src or v-ras was not able to phosphorylate MEK. Raf-1 phosphorylation of MEK activated it, as judged by its ability to stimulate the phosphorylation of myelin basic protein by glutathione S-transferase-ERK1. We conclude that MEK is a direct substrate of Raf-1 and that the activation of MEK by Raf-1 is due to phosphorylation by Raf-1, which is sufficient for MEK activation. We also tested the ability of protein kinase C to activate Raf-1 and found that, although protein kinase C phosphorylation of Raf-1 was able to stimulate its autokinase activity, it did not stimulate its ability to phosphorylate MEK.


Cell | 1995

Rac mediates growth factor-induced arachidonic acid release

Maikel P. Peppelenbosch; Rong-Guo Qiu; Alicia M.M de Vries-Smits; Leon G.J. Tertoolen; Siegfried W. de Laat; Frank McCormick; Alan Hall; Marc Symons; Johannes L. Bos

Growth factor-induced stress fiber formation involves signal transduction through Rac and Rho proteins and production of leukotrienes from arachidonic acid metabolism. In exploring the relationship between these pathways, we found that Rac is essential for EGF-induced arachidonic acid production and subsequent generation of leukotrienes and that Rac V12, a constitutively activated mutant of Rac, generates leukotrienes in a growth factor-independent manner. Leukotrienes generated by EGF or Rac V12 are necessary and sufficient for stress fiber formation. Furthermore, leukotriene-dependent stress fiber formation requires Rho proteins. We have therefore identified elements of a pathway from growth factor receptors that includes Rac, arachidonic acid production, arachidonic acid metabolism to leukotrienes, and leukotriene-dependent Rho activation. This appears to be the major pathway by which Rac influences Rho-dependent cytoskeleton rearrangements.


The EMBO Journal | 1997

Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro.

David Stokoe; Frank McCormick

The c‐Raf‐1 protein kinase plays a critical role in intracellular signaling downstream from many tyrosine kinase and G‐protein‐linked receptors. c‐Raf‐1 binds to the proto‐oncogene Ras in a GTP‐dependent manner, but the exact mechanism of activation of c‐Raf‐1 by Ras is still unclear. We have established a system to study the activation of c‐Raf‐1 in vitro. This involves mixing membranes from cells expressing oncogenic H–RasG12V, with cytosol from cells expressing epitope‐tagged full‐length wild‐type c‐Raf‐1. This results in a fraction of the c‐Raf‐1 binding to the membranes and a concomitant 10‐ to 20‐fold increase in specific activity. Ras was the only component in these membranes required for activation, as purified recombinant farnesylated K‐Ras.GTP, but not non‐farnesylated K–Ras.GTP or farnesylated K‐Ras.GDP, was able to activate c‐Raf‐1 to the same degree as intact H–RasG12V membranes. The most potent activation occurred under conditions in which phosphorylation was prohibited. Under phosphorylation‐permissive conditions, activation of c‐Raf‐1 by Ras was substantially inhibited. Consistent with the results from other groups, we find that the activation of c‐Raf‐1 by Src in vivo occurs concomitant with tyrosine phosphorylation on c‐Raf‐1, and in vitro, activation of c–Raf–1 by Src requires the presence of ATP. Therefore we propose that activation of c‐Raf‐1 by Ras or by Src occurs through different mechanisms.


Journal of Biological Chemistry | 1997

Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells.

Simon J. Cook; Jerlyn Beltman; Karen A. Cadwallader; Martin McMahon; Frank McCormick

Stimulation of Rat-1 cells with lysophosphatidic acid (LPA) or epidermal growth factor (EGF) results in a biphasic, sustained activation of extracellular signal-regulated kinase 1 (ERK1). Pretreatment of Rat-1 cells with either cycloheximide or sodium orthovanadate had little effect on the early peak of ERK1 activity but potentiated the sustained phase. Cycloheximide also potentiated ERK1 activation in Rat-1 cells expressing ΔRaf-1:ER, an estradiol-regulated form of the oncogenic, human Raf-1. Since cycloheximide did not potentiate MEK activity but abrogated the expression of mitogen-activated protein kinase phosphatase (MKP-1) normally seen in response to EGF and LPA, we speculated that the level of MKP-1 expression may be an important regulator of ERK1 activity in Rat-1 cells. Inhibition of LPA-stimulated MEK and ERK activation with PD98059 and pertussis toxin, a selective inhibitor of Gi-protein-coupled signaling pathways, reduced LPA-stimulated MKP-1 expression by only 50%, suggesting the presence of additional MEK- and ERK-independent pathways for MKP-1 expression. Specific activation of the MEK/ERK pathway by ΔRaf-1:ER had little or no effect on MKP-1 expression, suggesting that activation of the Raf/MEK/ERK pathway is necessary but not sufficient for MKP-1 expression in Rat-1 cells. Activation of PKC played little part in growth factor-stimulated MKP-1 expression, but LPA- and EGF-induced MKP-1 expression was blocked by buffering [Ca2+] i , leading to a potentiation of the sustained phase of ERK1 activation without potentiating MEK activity. In Rat-1ΔRaf-1:ER cells, we observed a strong synergy of MKP-1 expression when cells were stimulated with estradiol in the presence of ionomycin, phorbol 12-myristate 13-acetate, or okadaic acid under conditions where these agents did not synergize for ERK activation. These results suggest that activation of the Raf/MEK/ERK pathway is insufficient to induce expression of MKP-1 but instead requires other signals, such as Ca2+, to fully reconstitute the response seen with growth factors. In this way, ERK-dependent and -independent signals may regulate MKP-1 expression, the magnitude of sustained ERK1 activity, and therefore gene expression.


Molecular Medicine Today | 1996

Replicating viruses as selective cancer therapeutics

David Kirn; Frank McCormick

Replication-competent viruses are used as selective cancer therapeutics and the mechanisms leading to tumor-specific replication and antitumoral efficacy are now becoming apparent. The specific viruses in development include tumor-targeting herpes simplex viruses, autonomous parvoviruses, Newcastle disease viruses and adenovirus. Information is also available on antiviral immunology and viral defenses against host-mediated immunity. This approach has many potential attributes, in addition to potential hurdles that must be overcome.

Collaboration


Dive into the Frank McCormick's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marc Symons

The Feinstein Institute for Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arie Abo

Onyx Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge